Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors
Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) elicited favorable response rates in a mixed histology cohort of pretreated patients with solid tumors, lymphomas, and multiple myeloma whose tumors harbored a BRAF V600 mutation, meeting the primary end point of the NCI-MATCH EAY131-H trial.1 Results […]
Read More